The Technical Analyst
AccuStem Sciences Limited [ACMSY]
Exchange: OTC Sector: Healthcare Industry: Diagnostics & Research
AccuStem Sciences Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.14% $0.130
America/New_York / 31 des 1970 @ 19:00
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 10.51 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0970 - 0.173 ( +/- 28.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-12-30 | Cerrone Gabriele M | Buy | 5 000 | Common Stock |
| 2022-12-02 | Cerrone Gabriele M | Buy | 3 729 | Common Stock |
| 2022-11-18 | Cerrone Gabriele M | Buy | 24 500 | Common Stock |
| 2021-12-01 | Simon Willy Jules | Sell | 0 | Common Stock |
| 2021-08-01 | Simon Willy Jules | Sell | 1 464 | Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 13 transactions |
| Buy: 33 229 | Sell: 601 665 |
Forecast:
01:40 - $0.109
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.130 (-7.14% ) |
| Volume | 0.0012 mill |
| Avg. Vol. | 0.0182 mill |
| % of Avg. Vol | 6.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACMSY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACMSY
Accustem Sciences Limited engages in the genomic signature-based assay business for the prognosis of early and late recurrence of ER+/HER2 breast cancer in early stage breast cancer patients. The company was incorporated in 2020 and is based in London, the United Kingdom.